You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
In contrast to the stock market's rough start to 2008, consider the robust health of Johnson & Johnson (symbol JNJ), the world's largest and most diversified maker of health-care products. J&J stock closed at $67.80 on January 9, up 1.3%. So far in 2008, JNJ has gained 1.6% while Standard & Poor's 500-stock index has shed 4%.
What's the news driving this behemoth (estimated 2008 revenues: $63 billion)? There is no news, and that's just the point. J&J is the type of defensive, rock-solid global company that starts to look attractive in a weakening American economy.
Incorporated in 1887, J&J is one of the last triple-A rated corporations in the land. The company has paid dividends every quarter since going public in 1944 and raised those dividends 44 consecutive years. Today's market is one that values and rewards consistency and reliability like this.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
J&J breaks down into three major divisions: pharmaceuticals, medical devices and consumer products. Consumer brands such as Band-Aid, Tylenol, Neutrogena and Listerine have the most visibility, but the bulk of sales and profits come from drugs and devices such as DePuy orthopedic joint reconstruction and spinal products.
This year will be a bit rough for the pharma business because two multi-billion dollar drugs -- antipsychotic Risperdal and Topamax, a migraine and epilepsy treatment -- come off patent. But Remicade, a leading arthritis medication, is a blockbuster, and sales of ADHD drug Concerta continue to expand.
UBS says J&J, which spends $7 billion a year on research and development, has a particularly promising drug pipeline after 2009. The company just received FDA approval for an obesity treatment.
The diversity and breadth of J&J lends stability. Growth in the drug division may lag this year, but consumer products and medical equipment, such as blood-glucose monitoring devices, will pick up the slack.
Much of that growth will be driven by foreign sales; J&J does business in 175 countries and books nearly half of its sales abroad. According to Morningstar, the company can squeeze out 10% a year growth in revenues over the next three years, a respectable showing for a company of this size in a weak economic environment.
But it's the financial strength of J&J that attracts investors in today's weak economy. The company earns a high return on equity of 28% -- that's earnings before dividends divided by net worth. Its cash exceeds its long-term debt. And it generates a huge free cash flow (operating cash flow minus capital spending) of more than $12 billion a year.
This free cash flow -- which can be used to repurchase stock, raise dividends (the current yield is 2.5%) or make acquisitions -- is a lofty 20% of sales. The stock's free cash flow yield of 6.4% is relatively high for a company of this quality and consistency.
It is financial characteristics such as these (not to mention J&J's strong management and brands) that may be attracting Warren Buffett to the stock. In the quarter ended last September, Buffett's Berkshire Hathaway (BRK-A) purchased 8.5 million shares of JNJ, raising its stake in the health care company to 62 million shares.
UBS has a 12-month $77 price target on J&J stock. Adding in the 2.5% dividend, that implies a healthy 16% return on a blue chip. So far, so good.
-
How Much It Costs to Host a Super Bowl Party in 2026Hosting a Super Bowl party in 2026 could cost you. Here's a breakdown of food, drink and entertainment costs — plus ways to save.
-
3 Reasons to Use a 5-Year CD As You Approach RetirementA five-year CD can help you reach other milestones as you approach retirement.
-
Your Adult Kids Are Doing Fine. Is It Time To Spend Some of Their Inheritance?If your kids are successful, do they need an inheritance? Ask yourself these four questions before passing down another dollar.
-
If You'd Put $1,000 Into AMD Stock 20 Years Ago, Here's What You'd Have TodayAdvanced Micro Devices stock is soaring thanks to AI, but as a buy-and-hold bet, it's been a market laggard.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
How the Stock Market Performed in the First Year of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
Dow Rises 497 Points on December Rate Cut: Stock Market TodayThe basic questions for market participants and policymakers remain the same after a widely expected Fed rate cut.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
